The Treat FTD Fund: Clinical trials for FTD from The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation support the development of drugs or devices for FTD disorders while building a better understanding of FTD pathophysiology, biological mechanisms of disease, and analytically and clinically validated biomarkers with a well-defined context-of-use. This call seeks to support early-stage clinical trials incorporating:
- biological mechanisms that have a sound scientific rationale for FTD
- biomarkers that would permit evaluation of target engagement, downstream pharmacologic effect, and biological effect
- trial designs aligned with constraints associated with a rare disease population
- clinical outcome measures that could provide a deeper understanding of the drug mechanism and disease progression
- therapeutics applicable to sporadic or genetic forms of FTD. Trials of treatments applicable in sporadic FTD are especially encouraged.
Funding is open to researchers and clinicians worldwide at:
- Academic medical centers and universities; non-profits. Industry partnerships are encouraged.
- Biotechnology companies (existing companies or new spinouts) that demonstrate a clear need for non-profit funding. Funding is provided through mission-related investments (MRIs) that require a return on investment based on scientific and/or business milestones. Both existing companies and new spinouts are eligible.
The funding provides up to 250,000 USD for 1 to 3 years, based on the stage and scope of the trial. Co-funding from other funding agencies or investors is encouraged.
Letters of Intent are due on March 30, 2026, and invited full proposals are due on June 1, 2026.